loading...| Preferred Name |
everolimus |
|
| Synonyms |
42-O-(2-hydroxy)ethyl rapamycin |
|
| Definitions |
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48387" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48387" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000372905 |
|
| altLabel |
42-O-(2-hydroxy)ethyl rapamycin RAD001 Afinitor Certican Zortress Votubia Afinitor Disperz |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000438715 http://purl.bioontology.org/ontology/PDQ/CDR0000426487 http://purl.bioontology.org/ontology/PDQ/CDR0000391021 |
|
| cui |
C3640993 C4287668 C2682856 C2756938 C1174751 C0541315 C0962969 |
|
| DATE FIRST PUBLISHED |
2004-05-28 |
|
| Date last modified |
2018-04-13 |
|
| definition |
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48387" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48387" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C48387 |
|
| notation |
CDR0000372905 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
everolimus |
|
| tui |
T109 T121 |